RARA and thyroid cancer: LBX2-AS1 upregulates the expression of FSTL3 by recruiting RARα to the FSTL3 promoter, which suggests that FSTL3 may play a role in accelerating the progression of thyroid cancer (Figure 2G) (Li et al., 2021b).